PedAM
Pediatric Disease Annotations & Medicines
| Disease | acute pancreatitis |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 17 |
| PubMedID- 23700194 | [28] reported a higher rate of hospitalizations for acute pancreatitis in patients with type 2 diabetes associated with the use of incretin-based therapies (sitagliptin or exenatide). |
| PubMedID- 26059826 | Clinical and nonclinical studies have implicated glucagon-like peptide-1 (glp-1) receptor agonist therapy as a risk factor for acute pancreatitis in patients with type 2 diabetes. |
| PubMedID- 26512613 | To investigate the effects of dipeptidyl peptidase-4 (dpp-4) inhibitors on the risk of acute pancreatitis in patients with type 2 diabetes.this nationwide population-based cohort study used the diabetes patients dataset of taiwan's national health research insurance research database. |
| PubMedID- 23300896 | Background: increased risks of acute pancreatitis in patients with type 2 diabetes mellitus have been reported recently in several countries. |
| PubMedID- 24859164 | acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. |
| PubMedID- 24622714 | Larger studies are needed to clarify whether age or type of incretin therapy could affect the risk of acute pancreatitis in patients with type 2 diabetes. |
| PubMedID- 20682680 | (11) recently reported a lower risk of acute pancreatitis in patients with type 2 diabetes (adjusted hr of 1.49). |
| PubMedID- 20412332 | Recent case reports of acute pancreatitis in patients with type 2 diabetes (t2dm) treated with incretin-based therapies have triggered interest regarding the possibility of a mechanism-based association between pancreatitis and glucagon-like peptide-1 mimetics or dipeptidyl peptidase-4 (dpp-4) inhibitors. |
| PubMedID- 25918533 | If pancreatic autoantibodies are negative, patients have secondary diabetes due to pancreatitis or type 2 diabetes complicated by acute pancreatitis. |
| PubMedID- 24651798 | That study used a large insurance database of more than 1 million people, and reported increased odds of hospitalizations for acute pancreatitis in patients with type 2 diabetes 64 years of age or younger that were prescribed either exenatide or saxagliptin. |
| PubMedID- 20833867 | The results of this study confirm the excess risk of acute pancreatitis associated with type 2 diabetes previously reported in other observational studies (2,4,5). |
| PubMedID- 23440284 | Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. |
| PubMedID- 21577242 | Objectives: the objective of this study was to assess the risk of acute pancreatitis among patients with type 2 diabetes mellitus (dm) and identify the roles of co-morbidities and anti-diabetic drugs. |
| PubMedID- 26269615 | Glucagon-like peptide-1 (glp-1) receptor agonist therapy has been implicated as a possible risk factor for acute pancreatitis in patients with type 2 diabetes. |
| PubMedID- 24764569 | Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. |
| PubMedID- 23882053 | Other studies have examined lipase and amylase activities in serum (20) and the incidence of acute pancreatitis in patients with type 2 diabetes while receiving different forms of antidiabetes treatment (21–26). |
| PubMedID- 21525466 | Up-to-date observational reports and clinical study data revealed that 44 cases of acute pancreatitis occurred in patients with type 2 diabetes while taking exenatide (8 cases during clinical development and 36 postmarketing reports), 4 cases of pancreatitis in liraglutide-treated patients (in clinical trials), and none during therapy with albiglutide or taspoglutide (51). |
Page: 1